| Oct 29 |
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
|
| Oct 15 |
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
|
| Oct 8 |
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
|
| Sep 17 |
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
|
| Sep 12 |
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
|
| Sep 3 |
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 22 |
NKGen Biotech receives non-compliance notification from Nasdaq
|
| Aug 22 |
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
|
| Jul 30 |
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
|
| Jul 22 |
Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
|
